Artisan Pharma enrolls 750 patients in Phase 2b study of ART-123 in sepsis individuals with DIC Artisan Pharma, Inc. The clinical trial was a randomized, double-blind, placebo-controlled Phase 2b study to measure the efficacy and safety of ART-123 in individuals with sepsis and DIC. The clinical study enrolled 750 individuals in over 150 sites worldwide http://farmaciaunica.com/kamagra-gold/ .We.T. Inder Kaul, M.D., M.P.H., Chief Medical Officer of Artisan Pharma. We are energized at having reached this milestone and now will be concentrating on preparing to analyze the outcomes, which are anticipated by the medical and scientific communities highly.